Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis
Aim: Phosphorodiamidate morpholino oligomers (PMOs) are exon-skipping therapies administered through once-weekly intravenous infusions used to treat Duchenne muscular dystrophy (DMD). This study assessed treatment patterns among patients with DMD receiving PMOs using administrative claims data wh...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-07-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411475101188096 |
|---|---|
| author | Shannon Grabich Brian Ung Aalok Nadkar Kathryn DeYoung James Signorovitch Aravindhan Veerapandiyan |
| author_facet | Shannon Grabich Brian Ung Aalok Nadkar Kathryn DeYoung James Signorovitch Aravindhan Veerapandiyan |
| author_sort | Shannon Grabich |
| collection | DOAJ |
| description | Aim: Phosphorodiamidate morpholino oligomers (PMOs) are exon-skipping therapies administered
through once-weekly intravenous infusions used to treat Duchenne muscular dystrophy (DMD). This study
assessed treatment patterns among patients with DMD receiving PMOs using administrative claims data
while accounting for limitations in claims data for these therapies. Materials & methods: This study
used Inovalon R public and private closed claims data (1 June 2016–31 March 2024). Male patients with
≥1 claim for a PMO approved for DMD in the US (eteplirsen, casimersen, golodirsen and viltolarsen)
were included. Index date was the first PMO claim. All available follow-up data were used to assess
continuous PMO claims coverage, ≥60-day and ≥30-day gaps in PMO claims and PMO re-initiation after
a gap. Adherence during 1 year after index was measured using proportion of days covered (PDC).
Treatment patterns were also assessed in patients stratified by baseline algorithm-defined nonambulatory
status (inferred from claims). Results: Among 397 patients included, median (IQR) follow-up time was
788 (484, 1109) days. Gaps in PMO claims coverage occurred in 190 (47.9%) and 254 (64.0%) patients
using ≥60-day and ≥30-day gaps, respectively, among whom 110 (57.9%) and 176 (69.3%) had PMO reinitiation.
Using ≥60-day and ≥30-day gap lengths, median (IQR) time to first gap in PMO claims was
25.5 (22.3, 32.9) months and 13.5 (10.2, 17.7) months, respectively and median (IQR) time to PMO reinitiation
(not including gap time) was 4.4 (2.8, 8.7) months and 2.5 (1.7, 3.2) months. Median (IQR)
PDC was 78.8% (38.8, 94.0) during 1 year after index. PMO treatment patterns were generally similar in
patients stratified by algorithm-defined nonambulatory status. Conclusion: In an analysis of administrative
claims data, adherence to PMO treatment for DMD was high. For patients with a gap in PMO
claims, most subsequently re-initiated treatment, indicating lower discontinuation rates than previously
reported. |
| format | Article |
| id | doaj-art-8686004c91c047c1833c84f7af81b24e |
| institution | Kabale University |
| issn | 2042-6313 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj-art-8686004c91c047c1833c84f7af81b24e2025-08-20T03:34:45ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132025-07-0114810.57264/cer-2025-0037Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysisShannon Grabich0https://orcid.org/0000-0003-3474-6874Brian Ung1Aalok Nadkar2https://orcid.org/0000-0003-0158-9905Kathryn DeYoung3https://orcid.org/0000-0002-5439-7344James Signorovitch4https://orcid.org/0000-0002-4067-8962Aravindhan Veerapandiyan5https://orcid.org/0000-0002-3065-3956Sarepta Therapeutics, Inc, Cambridge, MA 02142 USASarepta Therapeutics, Inc, Cambridge, MA 02142 USASarepta Therapeutics, Inc, Cambridge, MA 02142 USASarepta Therapeutics, Inc, Cambridge, MA 02142 USAAnalysis Group, Inc, Boston, MA 02199, USAUniversity of Arkansas for Medical Sciences, Arkansas Children’s Hospital, Little Rock, AR 72202, USAAim: Phosphorodiamidate morpholino oligomers (PMOs) are exon-skipping therapies administered through once-weekly intravenous infusions used to treat Duchenne muscular dystrophy (DMD). This study assessed treatment patterns among patients with DMD receiving PMOs using administrative claims data while accounting for limitations in claims data for these therapies. Materials & methods: This study used Inovalon R public and private closed claims data (1 June 2016–31 March 2024). Male patients with ≥1 claim for a PMO approved for DMD in the US (eteplirsen, casimersen, golodirsen and viltolarsen) were included. Index date was the first PMO claim. All available follow-up data were used to assess continuous PMO claims coverage, ≥60-day and ≥30-day gaps in PMO claims and PMO re-initiation after a gap. Adherence during 1 year after index was measured using proportion of days covered (PDC). Treatment patterns were also assessed in patients stratified by baseline algorithm-defined nonambulatory status (inferred from claims). Results: Among 397 patients included, median (IQR) follow-up time was 788 (484, 1109) days. Gaps in PMO claims coverage occurred in 190 (47.9%) and 254 (64.0%) patients using ≥60-day and ≥30-day gaps, respectively, among whom 110 (57.9%) and 176 (69.3%) had PMO reinitiation. Using ≥60-day and ≥30-day gap lengths, median (IQR) time to first gap in PMO claims was 25.5 (22.3, 32.9) months and 13.5 (10.2, 17.7) months, respectively and median (IQR) time to PMO reinitiation (not including gap time) was 4.4 (2.8, 8.7) months and 2.5 (1.7, 3.2) months. Median (IQR) PDC was 78.8% (38.8, 94.0) during 1 year after index. PMO treatment patterns were generally similar in patients stratified by algorithm-defined nonambulatory status. Conclusion: In an analysis of administrative claims data, adherence to PMO treatment for DMD was high. For patients with a gap in PMO claims, most subsequently re-initiated treatment, indicating lower discontinuation rates than previously reported.adherenceduchenne muscular dystrophyexon-skipping therapiespersistencephosphorodiamidate morpholino oligomerstreatment patterns |
| spellingShingle | Shannon Grabich Brian Ung Aalok Nadkar Kathryn DeYoung James Signorovitch Aravindhan Veerapandiyan Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis Journal of Comparative Effectiveness Research adherence duchenne muscular dystrophy exon-skipping therapies persistence phosphorodiamidate morpholino oligomers treatment patterns |
| title | Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis |
| title_full | Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis |
| title_fullStr | Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis |
| title_full_unstemmed | Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis |
| title_short | Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis |
| title_sort | real world phosphorodiamidate morpholino oligomer treatment patterns in duchenne muscular dystrophy a claims based analysis |
| topic | adherence duchenne muscular dystrophy exon-skipping therapies persistence phosphorodiamidate morpholino oligomers treatment patterns |
| work_keys_str_mv | AT shannongrabich realworldphosphorodiamidatemorpholinooligomertreatmentpatternsinduchennemusculardystrophyaclaimsbasedanalysis AT brianung realworldphosphorodiamidatemorpholinooligomertreatmentpatternsinduchennemusculardystrophyaclaimsbasedanalysis AT aaloknadkar realworldphosphorodiamidatemorpholinooligomertreatmentpatternsinduchennemusculardystrophyaclaimsbasedanalysis AT kathryndeyoung realworldphosphorodiamidatemorpholinooligomertreatmentpatternsinduchennemusculardystrophyaclaimsbasedanalysis AT jamessignorovitch realworldphosphorodiamidatemorpholinooligomertreatmentpatternsinduchennemusculardystrophyaclaimsbasedanalysis AT aravindhanveerapandiyan realworldphosphorodiamidatemorpholinooligomertreatmentpatternsinduchennemusculardystrophyaclaimsbasedanalysis |